These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37065601)

  • 21. Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Xu Y; Li H; Fan Y
    Front Oncol; 2021; 11():642883. PubMed ID: 33747966
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Bahig H; Tonneau M; Blais N; Wong P; Filion E; Campeau MP; Vu T; Al-Saleh A; Tehfé M; Florescu M; Roberge D; Masucci L; Richard C; Menard C; Routy B
    Clin Transl Radiat Oncol; 2022 Mar; 33():115-119. PubMed ID: 35243022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression.
    Ho CB; Tsai JT; Chen CY; Shiah HS; Chen HY; Ting LL; Kuo CC; Lai IC; Lai HY; Chung CL; Lee KL; Tzeng HE; Lee KH; Lee HL; Chen SW; Chiou JF
    Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease?
    Aquilano M; Loi M; Visani L; Livi L; Nuyttens JJ
    Acta Oncol; 2023 Mar; 62(3):298-304. PubMed ID: 36905644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection.
    Franzese C; Perrino M; Marzo MA; Badalamenti M; Baldaccini D; D'Agostino G; Marini B; De Vincenzo F; Zucali PA; Scorsetti M
    Clin Exp Metastasis; 2022 Jun; 39(3):449-457. PubMed ID: 35190933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Local ablative therapy of oligoprogressive TKI-treated thyroid cancer.
    Porcelli T; Sessa F; Luongo C; Salvatore D
    J Endocrinol Invest; 2019 Aug; 42(8):871-879. PubMed ID: 30628046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.
    Donini M; Buti S; Massari F; Mollica V; Rizzo A; Montironi R; Bersanelli M; Santoni M
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):491-501. PubMed ID: 32479120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors.
    He L; Liu Y; Han H; Liu Z; Huang S; Cao W; Liu B; Qin Z; Guo S; Zhang Z; Lin M; Jiang X; Lin C; Li Y; Yao K; Dong P; Zhou F
    Am J Clin Oncol; 2020 Jan; 43(1):58-63. PubMed ID: 31651452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention.
    Staehler M; Haseke N; Zilinberg E; Stadler T; Karl A; Siebels M; Dürr HR; Siegert S; Jauch KW; Bruns CJ; Stief CG
    Urol Oncol; 2010; 28(2):139-44. PubMed ID: 19576802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
    Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic body radiotherapy prolongs the progression-free survival and delays the change of systemic therapy regimen in patients with lung oligoprogressive metastatic colorectal cancer.
    Li S; Dong D; Geng J; Zhu X; Shi C; Zhang Y; Wang H; Zhou S; Wu H; Cai Y; Li Y; Wang W
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e64-e72. PubMed ID: 33629479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
    De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
    Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease.
    Xu Q; Liu H; Meng S; Jiang T; Li X; Liang S; Ren S; Zhou C
    J Cancer; 2019; 10(2):522-529. PubMed ID: 30719148
    [No Abstract]   [Full Text] [Related]  

  • 36. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
    Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease.
    Ramadan S; Quan K; Schnarr K; Juergens RA; Hotte SJ; Mukherjee SD; Kapoor A; Meyers BM; Swaminath A
    Acta Oncol; 2022 Jun; 61(6):705-713. PubMed ID: 35435129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis.
    Ozluk AA; Karateke M; Sanli UA; Karaca B
    Melanoma Res; 2023 Oct; 33(5):417-421. PubMed ID: 37276020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.